Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to opt for frequent surveillance and/or prophylactic surgery (bilateral mastectomy and/or oophorectomy). Here, a follow-up is described for 63 healthy women at 50% risk of being a BRCA1/BRCA2 mutation carrier who underwent genetic testing. The course of distress and problems regarding body image and sexuality up to 1 year after disclosure of the test-outcome were described separately for mutation carriers undergoing mastectomy (n = 14), for mutation carriers opting for surveillance (n = 12) and for non-mutation carriers (n = 37). Furthermore, we analyzed whether women opting fo...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian c...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
To explore long-term psychosocial consequences of carrying a BRCA1/2 mutation and to identify possib...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
Women with a BRCA mutation face a complex choice between breast cancer surveillance and prophylactic...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whethe...
Contains fulltext : 88586.pdf (publisher's version ) (Closed access)Women with a B...
This study sought to investigate the impact of BRCA1 and BRCA2 mutation searching on women previousl...
Objective: Female BRCA1/2 mutation carriers are at increased risk of breast and ovarian cancer. Annu...
Objective: Female BRCA1/2 mutation carriers are at increased risk of breast and ovarian cancer. Annu...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian c...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
To explore long-term psychosocial consequences of carrying a BRCA1/2 mutation and to identify possib...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
Women with a BRCA mutation face a complex choice between breast cancer surveillance and prophylactic...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whethe...
Contains fulltext : 88586.pdf (publisher's version ) (Closed access)Women with a B...
This study sought to investigate the impact of BRCA1 and BRCA2 mutation searching on women previousl...
Objective: Female BRCA1/2 mutation carriers are at increased risk of breast and ovarian cancer. Annu...
Objective: Female BRCA1/2 mutation carriers are at increased risk of breast and ovarian cancer. Annu...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
International audienceIn a French national cohort of unaffected females carriers/non-carriers of a B...
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian c...